JP2018511327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511327A5 JP2018511327A5 JP2017551176A JP2017551176A JP2018511327A5 JP 2018511327 A5 JP2018511327 A5 JP 2018511327A5 JP 2017551176 A JP2017551176 A JP 2017551176A JP 2017551176 A JP2017551176 A JP 2017551176A JP 2018511327 A5 JP2018511327 A5 JP 2018511327A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- ankyrin repeat
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 55
- 102000008102 Ankyrins Human genes 0.000 claims 19
- 108010049777 Ankyrins Proteins 0.000 claims 19
- 102000023732 binding proteins Human genes 0.000 claims 18
- 108091008324 binding proteins Proteins 0.000 claims 18
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 102000057308 human HGF Human genes 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15162511.8 | 2015-04-02 | ||
| EP15162502.7 | 2015-04-02 | ||
| EP15162502 | 2015-04-02 | ||
| EP15162511 | 2015-04-02 | ||
| PCT/EP2016/057272 WO2016156596A1 (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511327A JP2018511327A (ja) | 2018-04-26 |
| JP2018511327A5 true JP2018511327A5 (enExample) | 2018-11-22 |
| JP6552636B2 JP6552636B2 (ja) | 2019-07-31 |
Family
ID=55650423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551176A Active JP6552636B2 (ja) | 2015-04-02 | 2016-04-01 | 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9458211B1 (enExample) |
| EP (2) | EP4272838A3 (enExample) |
| JP (1) | JP6552636B2 (enExample) |
| KR (2) | KR102427117B1 (enExample) |
| CN (1) | CN107454904A (enExample) |
| AU (3) | AU2016240220B2 (enExample) |
| BR (1) | BR112017020986A2 (enExample) |
| CA (1) | CA2979602C (enExample) |
| CL (1) | CL2017002454A1 (enExample) |
| CO (1) | CO2017009954A2 (enExample) |
| ES (1) | ES2953482T3 (enExample) |
| IL (2) | IL276944B (enExample) |
| MX (2) | MX2022008302A (enExample) |
| MY (1) | MY179505A (enExample) |
| NZ (1) | NZ735803A (enExample) |
| PH (1) | PH12017501792B1 (enExample) |
| RU (1) | RU2769470C2 (enExample) |
| SA (1) | SA517390092B1 (enExample) |
| SG (1) | SG11201707606RA (enExample) |
| WO (1) | WO2016156596A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
| CN103403024B (zh) * | 2010-11-26 | 2017-08-11 | 分子组合公司 | 设计的锚蛋白重复蛋白的改进的n‑端加帽模块 |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| EP3487518A4 (en) | 2016-07-20 | 2020-08-12 | Aerpio Therapeutics LLC | HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS) |
| EP3515933B9 (en) * | 2016-09-22 | 2023-08-16 | Molecular Partners AG | Recombinant binding proteins and their use |
| CN110959015B (zh) * | 2017-07-12 | 2023-07-25 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
| KR20200038303A (ko) * | 2017-08-18 | 2020-04-10 | 캠브리지 엔터프라이즈 리미티드 | 모듈형 결합 단백질 |
| JP7695187B2 (ja) | 2018-09-24 | 2025-06-18 | アイポイント ファーマシューティカルズ， インコーポレイテッド | ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体 |
| CN119930814A (zh) * | 2019-03-22 | 2025-05-06 | 反射制药有限公司 | 针对vegf的d-肽化合物 |
| US20220298212A1 (en) | 2019-06-04 | 2022-09-22 | Molecular Partners Ag | Recombinant 4-1bb binding proteins and their use |
| UY38739A (es) * | 2019-06-04 | 2020-12-31 | Molecular Partners Ag | Proteínas multiespecíficas |
| WO2020245171A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Designed ankyrin repeat domain with improved stability |
| US20220242973A1 (en) * | 2019-06-04 | 2022-08-04 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| BR112022011456A2 (pt) * | 2019-12-11 | 2022-08-23 | Molecular Partners Ag | Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas |
| CN114945584A (zh) | 2019-12-11 | 2022-08-26 | 分子合作伙伴股份公司 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
| TW202208404A (zh) | 2020-05-06 | 2022-03-01 | 瑞士商分子組合公司 | 新穎錨蛋白重複結合蛋白質及其用途 |
| WO2021229076A1 (en) * | 2020-05-14 | 2021-11-18 | Molecular Partners Ag | Recombinant cd40 binding proteins and their use |
| US20240279290A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Multispecific proteins |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| IL303629A (en) | 2020-12-16 | 2023-08-01 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| US20240108746A1 (en) * | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
| CA3211381A1 (en) | 2021-03-09 | 2022-09-15 | Matteo Bianchi | Novel darpin based multi-specific t-cell engagers |
| AU2022233791A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| JP2024508969A (ja) | 2021-03-09 | 2024-02-28 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ |
| WO2022190008A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Protease cleavable prodrugs |
| CN118354784A (zh) | 2021-12-14 | 2024-07-16 | 分子合作伙伴股份公司 | 具有双重结合特异性的经设计的重复结构域及其用途 |
| CN114957426B (zh) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | Sp6rars及其在防治蜚蠊目昆虫中的应用 |
| AU2023317655A1 (en) | 2022-08-01 | 2025-01-23 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2024251742A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd2 binding proteins and their use |
| WO2024251695A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd47 binding proteins and their use |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025146490A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Recombinant cd117 binding proteins and their use |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025146487A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Multispecific binding proteins |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| US20250332297A1 (en) | 2024-01-31 | 2025-10-30 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EA013615B1 (ru) | 2004-11-12 | 2010-06-30 | Байер Шеринг Фарма Акциенгезельшафт | Рекомбинантный онколитический парамиксовирус и его применение |
| EP3613767A1 (en) | 2005-05-18 | 2020-02-26 | Ablynx N.V. | Improved nanobodiestm against tumor cecrosis factor-alpha |
| JP5042218B2 (ja) | 2005-07-08 | 2012-10-03 | ユニバーシティ・オブ・チューリッヒ | 融合ポリペプチドの翻訳と同時のトランスロケーションを使用するファージディスプレイ |
| CA2644712C (en) | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| CN101970678B (zh) | 2007-06-21 | 2014-08-20 | 慕尼黑科技大学 | 具有增加的体内和/或体外稳定性的生物学活性蛋白 |
| EP2198022B1 (en) | 2007-09-24 | 2024-03-06 | University Of Zurich | Designed armadillo repeat proteins |
| CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| CN102781959A (zh) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽 |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| DK2590993T3 (en) * | 2010-07-09 | 2015-06-29 | Affibody Ab | Polypeptides |
| BR112013001429A2 (pt) * | 2010-07-19 | 2016-05-31 | Hoffmann La Roche | método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer |
| BR112013013003A2 (pt) | 2010-11-24 | 2016-08-09 | Glaxo Group Ltd | proteína de ligação de antígeno, e, composição farmacêutica |
| CN103403024B (zh) | 2010-11-26 | 2017-08-11 | 分子组合公司 | 设计的锚蛋白重复蛋白的改进的n‑端加帽模块 |
| EA201391607A1 (ru) | 2011-04-29 | 2014-04-30 | Янссен Байотек, Инк. | Связывающие il4/il13 белки с повторами и их применение |
| MX2014015825A (es) | 2012-06-28 | 2015-08-10 | Molecular Partners Ag | Proteinas de repeticion de anquirina diseñadas que se unen al factor de crecimiento derivado de plaquetas. |
| EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| EP3004152B1 (en) * | 2013-05-31 | 2020-09-30 | Molecular Partners AG | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
-
2016
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/pt not_active Application Discontinuation
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/es unknown
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/en active Pending
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/ko active Active
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/en active Active
- 2016-04-01 PH PH1/2017/501792A patent/PH12017501792B1/en unknown
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/ru active
- 2016-04-01 MX MX2017012485A patent/MX393655B/es unknown
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en not_active Ceased
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/zh active Pending
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/ko not_active Ceased
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en not_active IP Right Cessation
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/en not_active Ceased
- 2016-04-01 ES ES16713904T patent/ES2953482T3/es active Active
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/ja active Active
- 2016-04-01 CA CA2979602A patent/CA2979602C/en active Active
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/es unknown
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/es unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/ar unknown
-
2018
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511327A5 (enExample) | ||
| Hong et al. | Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote Ischaemic Preconditioning with Postconditioning Outcome Trial | |
| JP2015522576A5 (enExample) | ||
| JP2010202664A5 (enExample) | ||
| JPWO2019107530A5 (enExample) | ||
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| JP2016509011A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| JP2018522563A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP2012511545A5 (enExample) | ||
| JP2018503668A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| JP2019525898A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2013172743A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| JP2017532343A5 (enExample) | ||
| JP2015505843A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2012513193A5 (enExample) | ||
| JP2019531293A5 (enExample) |